Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13066644 | 0.81 | L3MBTL1 (0.65) | L3MBTL1PRMT1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29681615 | 0.81 | L3MBTL1 (0.65) | L3MBTL1PRMT1ATMMEN1KMT2A | |
| SCHEMBL1706579 | 0.81 | L3MBTL1 (0.65) | L3MBTL1PRMT1SMN1; SMN2ATMMEN1 | |
| SCHEMBL1706646 | 0.81 | L3MBTL1 (0.65) | L3MBTL1PRMT1ATMMEN1KMT2A | |
| SCHEMBL4249543 | 0.80 | L3MBTL1 (0.63) | L3MBTL1PRMT1ATMMEN1KMT2A | |
| SCHEMBL1873887 | 0.79 | PRMT1 (0.77) | L3MBTL1PRMT1SMN1; SMN2ATMMEN1 | |
| SCHEMBL3195623 | 0.78 | L3MBTL1 (0.56) | L3MBTL1PRMT1SMN1; SMN2ATMMEN1 | |
| SCHEMBL23083127 | 0.77 | L3MBTL1 (0.59) | L3MBTL1PRMT1ATMMEN1KMT2A | |
| SCHEMBL17489092 | 0.77 | L3MBTL1 (0.59) | L3MBTL1PRMT1MEN1KMT2ALMNA | |
| SCHEMBL28390369 | 0.77 | LMNA (0.58) | L3MBTL1SMN1; SMN2ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9287597-B2 | Ionic liquid containing hydroxamate and N-alkyl sulfamate ions | FLUIDIC, INC. (US) | 2016-03-15 | — | — | US | claimed |
| US-20150221999-A1 | IONIC LIQUID CONTAINING HYDROXAMATE AND N-ALKYL SULFAMATE IONS | FLUIDIC, INC. (US) | 2015-08-06 | — | — | US | claimed |
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | claimed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | claimed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | claimed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | claimed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | claimed |
| US-9287597-B2 | Ionic liquid containing hydroxamate and N-alkyl sulfamate ions | FLUIDIC, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150221999-A1 | IONIC LIQUID CONTAINING HYDROXAMATE AND N-ALKYL SULFAMATE IONS | FLUIDIC, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | BOLLI MARTIN | 2006-08-10 | — | — | US | disclosed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
| WO-2003082263-A1 | SULFAMIC ACIDS AS INHIBITORS OF HUMAN CYTOPLASMIC PROTEIN TYROSINE PHOSPHATASES | ONTOGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | EDNRA, EDNRB, ECE2 | L3MBTL1 4884/4885PRMT1 953/4885SMN1; SMN2 1494/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | L3MBTL1 4882/4885PRMT1 632/4885SMN1; SMN2 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.